---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-031061"
form_type: "8-K"
ticker: "BCTX"
cik: "0001610820"
company_name: "BriaCell Therapeutics Corp."
filed_at: "2023-08-31T23:59:59+00:00"
generated_at: "2026-06-11T01:14:56.569248+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# BriaCell closes spinout of BriaPro to shareholders; retains 66.6% stake

## Summary
- Closed plan of arrangement spinning out Bria-TILsRx™ and PKCδ inhibitors to BriaPro.
- Shareholders receive one BriaPro share and one new BriaCell share per existing share.
- BriaCell now owns ~66.6% (31,963,452 shares) of BriaPro's outstanding shares.
- BriaPro becomes unlisted reporting issuer in Canada; BriaCell remains on Nasdaq and TSX.
- New BriaCell common shares expected to trade on or about Sept 5, 2023 under 'BCT'.

## SEC filing metadata
- accession: 0001493152-23-031061
- form_type: 8-K
- ticker: BCTX
- cik: 0001610820
- company_name: BriaCell Therapeutics Corp.
- filed_at: 2023-08-31T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1610820/000149315223031061/0001493152-23-031061-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1610820/000149315223031061/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-031061
- JSON: https://secwatch.observer/filing/0001493152-23-031061.json
- Plain text: https://secwatch.observer/filing/0001493152-23-031061.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.